Publications by authors named "S Aleman"
Article Synopsis
- The study assessed the safety and tolerability of bulevirtide (BLV), a new treatment for chronic hepatitis delta (CHD), by analyzing data from three clinical trials involving 269 patients.
- The findings indicated that certain adverse events, such as increased bile acid levels and injection-site reactions, were more common with BLV compared to a control group, but serious side effects were minimal and did not lead to treatment discontinuation.
- Overall, BLV was deemed safe and well tolerated over 48 weeks of therapy in patients with CHD, showing promise as an effective treatment option.
Host genetics shape immune responses and influence severity of infectious diseases. The HLA-B -21 M/T dimorphism tunes the functionality of natural killer (NK) cells expressing the inhibitory receptor NKG2A. NKG2A NK cells have been reported to recognize SARS-CoV-2-infected cells, but it remains unclear whether the HLA-B -21 M/T dimorphism associates with COVID-19 severity.
View Article and Find Full Text PDFBackground: It is thought that patients with inborn errors of immunity (IEI) are more susceptible to severe coronavirus disease 2019 (COVID-19) than the general population, but a quantification of this potential risk is largely missing.
Objective: We assessed the impact of COVID-19 on patients with IEI.
Methods: A nationwide cohort study was performed to estimate the relative risk (RR) for hospitalization, intensive care, and death within 30 days after a positive severe acute respiratory syndrome coronavirus 2 test result in an IEI population (n = 2392) compared to the general population (n = 8,270,705) using data from Swedish national registries.
Article Synopsis
- Immunocompromised patients have shown weak responses to initial SARS-CoV-2 mRNA vaccinations, prompting recommendations for extra booster doses; however, real-world data on these recommendations is limited.
- A two-year follow-up of the COVAXID clinical trial involved 364 participants, focusing on their immune responses and the effects of their vaccination schedule and underlying health conditions.
- The study found that while some patients who initially had poor responses improved after additional doses, their immune response remained affected by their immunosuppressive status, emphasizing the need for ongoing vaccination efforts in these populations.
Background: Data on the outcomes of COVID-19 in people living with HIV (PLHIV), specifically in relation to vaccination status, are lacking during the Omicron era.
Methods: This nationwide registry-based study included all resident in Sweden ≥18 years with a positive SARS-CoV-2 PCR test during January 2021-February 2023. We estimated adjusted odds ratios (adjOR) for COVID-19 hospitalisation and severe COVID-19 (ICU admission and 90-day mortality), categorised by SARS-CoV-2 vaccination status (0-1, 2, and ≥3 doses), and HIV-status.